| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Beijing Centergate Technologies (holding) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.33 |
| 52 Week High | CN¥6.52 |
| 52 Week Low | CN¥3.27 |
| Beta | 0.60 |
| 1 Month Change | -7.48% |
| 3 Month Change | 2.85% |
| 1 Year Change | -29.13% |
| 3 Year Change | -38.32% |
| 5 Year Change | -45.74% |
| Change since IPO | -78.76% |
Recent News & Updates
Shareholder Returns
| 931 | CN Real Estate | CN Market | |
|---|---|---|---|
| 7D | 4.6% | 8.6% | 3.1% |
| 1Y | -29.1% | -25.6% | -13.1% |
Return vs Industry: 000931 underperformed the CN Real Estate industry which returned -25.6% over the past year.
Return vs Market: 000931 underperformed the CN Market which returned -13.1% over the past year.
Price Volatility
| 931 volatility | |
|---|---|
| 931 Average Weekly Movement | 8.6% |
| Real Estate Industry Average Movement | 7.4% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 000931 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000931's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2,434 | Zhanjun Hou | www.centek.com.cn |
Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical production and sales, construction, real estate development, and property management businesses in China and internationally. The company offers huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, naloxone hydrochloride, five plus biochemical, and aramol quramado tablets and capsules.
Beijing Centergate Technologies (holding) Co., Ltd. Fundamentals Summary
| 931 fundamental statistics | |
|---|---|
| Market cap | CN¥3.26b |
| Earnings (TTM) | CN¥50.95m |
| Revenue (TTM) | CN¥2.29b |
64.0x
P/E Ratio1.4x
P/S RatioIs 931 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 931 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.29b |
| Cost of Revenue | CN¥935.34m |
| Gross Profit | CN¥1.36b |
| Other Expenses | CN¥1.31b |
| Earnings | CN¥50.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 59.24% |
| Net Profit Margin | 2.22% |
| Debt/Equity Ratio | 35.4% |
How did 931 perform over the long term?
See historical performance and comparison